CEO Executive AssistantWhy Health Economics Is a CEO-Level Strategic Discipline
Health economics and outcomes research (HEOR) has moved from a technical support function to a central driver of pharmaceutical commercial success. In markets where payer gatekeeping determines whether a drug achieves meaningful patient access, the quality and timing of health economic evidence can make or break a product’s commercial trajectory.
Pharmaceutical CEOs who treat HEOR as a specialist back-office function are leaving competitive advantage on the table. The most commercially sophisticated companies in the industry build their health economics capabilities early in development, integrate HEOR strategy into brand planning, and use real-world evidence to continuously strengthen their value narratives in a dynamic payer environment.
This article provides a CEO-level operational framework for building and deploying health economics capabilities as a genuine strategic asset.
The Business Value of Health Economic Evidence
Payer Coverage and Formulary Positioning
In markets with formulary tiering, prior authorization requirements, and outcomes-based contracting, health economic evidence directly determines the commercial ceiling for a pharmaceutical product. A product with strong clinical trial results but weak cost-effectiveness evidence faces payer restrictions that limit prescribing volume regardless of physician preference.
Payers, pharmacy benefit managers, and health technology assessment (HTA) bodies increasingly require economic models that demonstrate value not just in clinical terms but in total cost of care terms. Cost per quality-adjusted life year (QALY), budget impact models, and comparative effectiveness analyses have become standard payer requirements in most major markets.
The CEO must ensure that the HEOR team has the resources, access to clinical data, and organizational mandate to produce this evidence on the timeline that payer engagement requires. This means starting health economic modeling early in Phase III, not at launch.
Pricing Strategy Support
Health economic evidence is the foundation of defensible drug pricing. When pharmaceutical companies can demonstrate that a drug’s price is commensurate with the clinical benefit it delivers and the downstream healthcare costs it avoids, pricing decisions are grounded in evidence rather than arbitrary judgment.
CEOs under pressure from payers, policymakers, and the public about drug pricing need robust health economic evidence to make their case. An internally developed economic model validated against independent real-world data is a far stronger defense of pricing than market comparisons alone.
The CFO and Chief Commercial Officer must work with the HEOR team to ensure that pricing strategy and health economic evidence development are synchronized. Launching a product at a price point before the supporting economic evidence is fully developed is a common and costly mistake.
Value-Based Contracts
Outcomes-based or value-based contracts between pharmaceutical companies and payers represent one of the most significant structural shifts in pharmaceutical market access. Under these arrangements, manufacturers agree to rebates or price adjustments based on whether patients achieve predefined clinical outcomes.
These contracts require sophisticated real-world data infrastructure to track patient outcomes at scale, and they require health economic models that can define appropriate outcome thresholds and calculate the financial implications of different performance scenarios. Building this capability is a CEO-level investment decision that enables access to payer segments that increasingly demand outcome accountability.
According to Forbes, value-based contracts in pharmaceuticals are growing rapidly as both payers and manufacturers seek to align financial incentives with clinical outcomes, particularly in high-cost specialty categories.
Building the HEOR Operational Infrastructure
Staffing and Organizational Structure
Effective HEOR operations require a combination of health economists, epidemiologists, biostatisticians, outcomes researchers, and evidence synthesis specialists. In smaller organizations, some of these roles are combined or supplemented through partnerships with contract research organizations (CROs) and academic centers. In larger companies, dedicated HEOR teams are embedded within market access or medical affairs.
The CEO must make a deliberate decision about the organizational home for HEOR. Embedding HEOR within market access emphasizes the commercial application of evidence. Embedding it within medical affairs emphasizes scientific independence. Either approach can work, but the reporting structure sends an organizational signal about how health economics is valued and used.
Regardless of organizational home, HEOR leaders should have a direct path to the CEO for major evidence strategy decisions, particularly those that affect pricing, payer negotiations, or market entry sequencing.
Real-World Data Infrastructure
Real-world evidence (RWE) is increasingly important for HEOR because payers want to see evidence beyond the controlled conditions of clinical trials. Real-world data sources include electronic health records, claims databases, patient registries, and wearable device data.
Building the infrastructure to access, analyze, and publish real-world evidence requires investment in data partnerships, analytical platforms, and research governance. CEOs must allocate budget not just for clinical development but for the post-approval evidence generation that sustains the brand’s value narrative over time.
Key infrastructure elements include: data use agreements with health systems and claims data vendors, analytical platforms capable of handling large longitudinal datasets, a research governance process that ensures data privacy compliance, and a publication strategy that gets RWE results into peer-reviewed journals and payer-facing formats.
Health Technology Assessment Readiness
In markets with formal HTA processes (including the United Kingdom, Germany, France, Canada, and increasingly others), the HEOR team must prepare comprehensive dossiers that present the clinical and economic evidence in the structured format each HTA body requires. These dossiers often run to hundreds of pages and must meet rigorous methodological standards.
The CEO must understand that HTA submissions are not just regulatory filings: they are commercial negotiations that determine price and access in major markets. A negative HTA decision can exclude a product from national formularies or impose severe price restrictions. Investing in HTA excellence, including experienced staff, external advisors, and early scientific advice meetings with HTA bodies, is one of the highest-ROI operational investments in pharmaceutical commercial operations.
Integrating HEOR into Brand Strategy
Early Development Integration
The most significant HEOR capability gap in the pharmaceutical industry is timing. Organizations that begin health economic thinking at launch are already too late. By that point, the clinical trial design is fixed, the comparator choice is locked in, and the label is largely determined. These upstream decisions have downstream HEOR consequences that cannot be undone.
The CEO must establish operational requirements for HEOR involvement at key development decision points: indication selection, trial design review, endpoint selection, comparator choice, and data collection planning. Health economists who understand the payer evidence requirements for the target market should have input into trial design, not just post hoc analysis.
This integration requires breaking down silos between clinical development and commercial operations, a cultural and structural change that requires CEO sponsorship. The return on investment is direct: better-designed trials produce more commercially useful evidence.
The pharma manufacturing excellence framework is a useful parallel: just as manufacturing quality standards must be built into production processes, not inspected in at the end, health economic evidence must be built into development processes, not retrofitted at launch.
Health Economic Models as Living Assets
A health economic model is not a one-time deliverable. It is a living analytical asset that should be updated as new clinical data emerges, real-world evidence accumulates, and competitive products enter the market.
The HEOR team should maintain a model library that includes: the core cost-effectiveness model for each major market, budget impact models calibrated to individual payer populations, comparative effectiveness analyses updated with new head-to-head data, and scenario analysis tools that allow the market access team to model different pricing and contract structures.
These models should be validated regularly against independent benchmarks and updated before every major payer negotiation or HTA submission.
Translating Evidence into Payer Value Stories
Health economic models are necessary but not sufficient for payer engagement. The evidence must be translated into compelling value narratives that resonate with payer decision-makers who are often not economists. The HEOR team works with market access and medical affairs to develop value story materials: economic summaries, budget impact calculators, and interactive tools that allow payers to model the drug’s impact in their own population.
The CEO ensures that value story development is adequately resourced and that materials are customized for different payer types: national health systems, commercial insurers, integrated delivery networks, and pharmacy benefit managers each have different priorities and decision frameworks.
Managing Health Economics in a Policy Environment
Responding to Drug Pricing Pressure
Pharmaceutical CEOs operate in an environment of sustained policy pressure on drug pricing. In the United States, the Inflation Reduction Act’s Medicare drug price negotiation provisions represent a structural shift in the pricing environment for high-cost products. In Europe, joint clinical assessment and HTA convergence are changing the evidence requirements for market access across multiple countries simultaneously.
HEOR capabilities are critical for navigating this environment. Organizations that can demonstrate robust, independently validated evidence of clinical value are better positioned to defend prices, engage constructively with policymakers, and develop credible rebate and outcomes-based contracting proposals.
The CEO should work with the Chief Policy Officer and HEOR leadership to develop a proactive policy engagement strategy that uses health economic evidence to shape, not just respond to, pricing and access policy.
Health Equity Considerations in HEOR
There is increasing recognition that health economic models can systematically undervalue therapies for populations with lower baseline quality of life, including elderly patients, patients with disabilities, and historically underserved communities. The HEOR community and some HTA bodies are actively developing methods to address this limitation.
Forward-thinking pharmaceutical CEOs are engaging with this issue proactively, incorporating health equity analyses into their HEOR programs and working with payers and HTA bodies to develop evidence frameworks that capture the full value of therapies for diverse patient populations. This is both an ethical responsibility and a commercial strategy: as population health equity gains prominence in healthcare policy, companies with credible equity-informed evidence will be better positioned for access and reimbursement.
See also pharma operations checklist for how HEOR governance fits within the broader pharmaceutical CEO operational framework.
Measuring HEOR Operational Performance
Like any business function, HEOR operations should be evaluated against defined performance metrics. The CEO and Chief Commercial Officer should track:
- HTA submission success rates and timeline adherence
- Payer coverage outcomes relative to market access targets
- Quality and impact of real-world evidence publications
- Value-based contract execution and performance
- HEOR talent retention and scientific reputation
These metrics connect the HEOR function to commercial outcomes in a measurable way, supporting the case for continued investment and enabling performance improvement over time.
Conclusion
Health economics and outcomes research is not a technical accessory to pharmaceutical commercial operations: it is a strategic core competency that determines market access, supports pricing, enables outcomes-based contracts, and defends the brand’s value narrative in an increasingly scrutinized industry environment.
The pharmaceutical CEO who builds HEOR capabilities early, integrates them into development decision-making, invests in real-world data infrastructure, and deploys health economic evidence proactively in payer and policy engagement is the CEO who gives their products the best possible commercial foundation. In a healthcare environment that is increasingly demanding evidence of value, HEOR excellence is a durable competitive advantage.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.